EGFR and colorectal cancer: The OPUS and CRYSTAL studies of colorectal cancer patients receiving the FOLFOX plus cetuximab and FOLFIRI plus cetuximab regimens, respectively, have demonstrated that mutations in codons 12 and 13 are negative predictive factor for the response to the anti-EGFR antibody cetuximab [9, 10].